^
    Back
    Association details:
    Biomarker:KRAS G12C + TP53 mutation
    Cancer:Non Small Cell Lung Cancer
    Drug Class:Immunotherapy
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Zhonghua Bing Li Xue Za Zhi
    Title:

    [Gene mutation profiles and clinicopathological features of patients with non-small cell lung cancer harboring KRAS G12C mutation: a single-center retrospective study]

    Published date:
    02/08/2023
    Excerpt:
    Patients with KRAS G12C mutation NSCLC treated with ICIs and KRAS G12C patients with TP53 mutation had significantly longer median PFS than those with STK11 mutation (9.0 months vs. 4.3 months, P=0.012).
    DOI:
    10.3760/cma.j.cn112151-20220629-00561